Efficacy and Safety of Nafamostat Mesilate Injection in Patients Receiving Continuous Renal Replacement Therapy: A Meta-Analysis
Journal of Visualized Experiments · 2026-10-30 · (236)
DOI: 10.3791/72188 ↗At a glance
Metaanalyse in Journal of Visualized Experiments, published online on 2026-10-30. Written by Yanting Tu and 5 co-authors. Institution: Intensive Care Unit (ICU), The Second Hospital of Jiaxing. Major MEDLINE topics: Guanidines, Continuous Renal Replacement Therapy, Anticoagulants.
Abstract (original language)
The objective of the study was to assess the efficacy and safety of nafamostat mesilate injection in patients receiving continuous renal replacement therapy (CRRT). Dichotomous and continuous outcomes were analyzed using fixed-effect or random-effects models to estimate odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs). Eight studies involving 1,189 patients were included in the meta-analysis. Compared with no anticoagulation, nafamostat mesilate injection was associated with lower mortality (OR, 0.58; 95% CI, 0.44-0.76; p < 0.001) and longer filter lifespan (MD, 7.00; 95% CI, 1.50-12.50; p = 0.01). These estimates were derived predominantly from nonrandomized studies and should be interpreted with caution. However, no significant difference was found between nafamostat mesilate injection and no anticoagulation in bleeding complications (OR, 1.09; 95% CI, 0.51-2.34; p = 0.82), total duration of CRRT (MD, 4.46; 95% CI, -0.13-9.04; p = 0.06), the proportion of patients requiring transfusion (OR, 0.75; 95% CI, 0.54-1.03; p = 0.07), and intensive care unit (ICU) length of stay (MD, -0.24; 95% CI, -3.85-3.37; p = 0.90) in patients receiving CRRT. The available evidence suggests that nafamostat mesilate injection may be associated with lower mortality and longer filter lifespan compared with no anticoagulation in patients receiving CRRT. However, no clear difference was observed in bleeding complications, total duration of CRRT, the proportion of patients requiring transfusion, or ICU length of stay. These findings are limited by the predominance of nonrandomized designs, small numbers of studies, and substantial heterogeneity. Additional adequately powered randomized studies are needed before clinical benefit can be considered established.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Intensive Care Unit (ICU), The Second Hospital of Jiaxing.
- Post-Anesthesia Care Unit (PACU), The Second Hospital of Jiaxing.
- Intensive Care Unit (ICU), The Second Hospital of Jiaxing; 15990344658@163.com.
Cite
APA
Tu, Y., Hu, Y., Lv, Q., Zhu, Q., Yu, Y., & Yao, B. (2026). Efficacy and Safety of Nafamostat Mesilate Injection in Patients Receiving Continuous Renal Replacement Therapy: A Meta-Analysis. Journal of Visualized Experiments. https://doi.org/10.3791/72188
Vancouver
Tu Y, Hu Y, Lv Q, Zhu Q, Yu Y, Yao B. Efficacy and Safety of Nafamostat Mesilate Injection in Patients Receiving Continuous Renal Replacement Therapy: A Meta-Analysis. Journal of Visualized Experiments. 2026. doi:10.3791/72188
BibTeX
@article{Tu2026,
author = {Tu, Yanting and Hu, Yuanmin and Lv, Qun and Zhu, Qinyan and Yu, Yanfei and Yao, Bingjie},
title = {Efficacy and Safety of Nafamostat Mesilate Injection in Patients Receiving Continuous Renal Replacement Therapy: A Meta-Analysis},
journal = {Journal of Visualized Experiments},
year = {2026},
number = {236},
doi = {10.3791/72188}
}
EUVIMED